EUCTR2007-007482-21-GB进行中（未招募）1 期
Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study
Salford Royal NHS Foundation Trust0 个研究点目标入组 0 人开始时间: 2009年8月17日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Must Provide written informed consent.Prior to any study proceedures being undertaken.
- •Already receiving Fabrazyme 1mg/kg body weight every 2 weeks.
- •Has confirmed Fabry Disease(documented )
- •eGFR >20 and <60 ml/min/1.73m2.and documented baseline urine protein/creatinine ratio >0.5 based on last value obtained before initiating ACE1/ARB therapy or obtained at screening before the first evaluation visit of FAACET Study.
- •eGFR<125ml/min/1.73m2 and >60ml/min/1.73m2 with documented baseline urine protein/creatinine ratio >1, based on the last value obtained before initiating ACE1/ARB therapy or obtained at screening before the first evaluation visit of the FAACET Study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The patient has undergone kidney transplant/is currently on dialysis/is planning on receiving a kidney transplnt during the first year of study.
- •Patient has diabetic nephropathy or the presence of another, confounding kidney disease unless there is kidney biopsy confirmation that the patient does not have diabetic nephropathy or another confounding kidney disease.
- •Patient has clinically significant organic disease,or other condirion that in the opinion of the investigator would preclude participation in the full extent of the trial.
- •The patient is unwilling to comply with the requirements of the protocol, including continuing on Fabrazyme at 1mg/kg body weight every two weeks.
- •Patients who have documented allergies to both ACE inhibitors and ARB's are not eligible to participate in the FAACET Study.
- •The patient is pregnant, or intends to become pregnant during the course of the study.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid ArthritisMedDRA version: 17.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersJuvenile Rheumatoid ArthritisEUCTR2014-004558-33-Outside-EU/EEAAbbott Japan Co., Ltd.25
进行中（未招募）
1 期
A Study of Trastuzumab-MCC-DM1 (T-DM1) in Combination With Docetaxel in Patients With Advanced Breast Cancer.EUCTR2009-010000-28-GBF. Hoffmann-La Roche Ltd98
进行中（未招募）
1 期
An open-label, multi-center study of the safety and tolerability of the combination of Trastuzumab-MCC-DM1 (T-DM1) with docetaxel, and potentially pertuzumab, for treatment for patients with advanced breast cancer.Treatment in patients with advanced, HER2-positive breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-010000-28-FRF. Hoffmann-La Roche Ltd98
暂停
1 期
A multi-centre study of the safety, tolerability and effects of intravenously administered Cyclic Pyranopterin Monophosphate (cPMP) in patients with molybdenum cofactor deficiency type A.ACTRN12609000849291PMP(Vic) Pty Ltd10
进行中（未招募）
4 期
Cephalexin Extended Release and Clavulanate Potassium Tablets in Patients with Upper Respiratory Tract Infection and Uncomplicated Skin & Soft Tissue Infection.CTRI/2022/07/044190Sun Pharma Laboratories Ltd